NYMC Faculty Publications

Low-Dose Colchicine for the Prevention of Cardiovascular Events After Acute Coronary Syndrome

Author Type(s)

Student, Faculty

DOI

10.1097/CRD.0000000000000650

Journal Title

Cardiology in Review

First Page

517

Last Page

521

Document Type

Article

Publication Date

12-1-2025

Department

Medicine

Keywords

acute coronary syndrome, atherosclerosis, cardiovascular events, colchicine, coronary artery disease

Disciplines

Medicine and Health Sciences

Abstract

Colchicine, an established anti-inflammatory drug, is examined for its potential in mitigating adverse cardiovascular events following acute coronary syndrome (ACS). ACS, primarily triggered by plaque rupture and subsequent thrombosis, is a critical cardiovascular condition. Colchicine’s mechanism of action involves inhibiting microtubule activity, leading to immobilization of white blood cells and reducing inflammation. Clinical data from studies, including low-dose colchicine for secondary prevention of cardiovascular disease two and colchicine cardiovascular outcomes trial, support its efficacy in reducing major cardiovascular events post-ACS, though some studies report varying results. Colchicine can cause transient gastrointestinal side effects and is prescribed with caution in patients with certain medical conditions. The recent FDA approval of a low dose of colchicine reiterates its benefit in reducing cardiovascular risk. The cost-effectiveness of colchicine products (0.5 and 0.6 mg doses) are compared, suggesting the generic 0.6 mg dose of colchicine to be an alternative to branded forms of the drug.

Link to Full Text

Share

COinS